Introduction
Chromosomal translocations lead to oncogene activation in hematological malignancies, where they play an important role both at diagnosis and as an indicator of prognosis. Rearrangements involving the immunoglobulin heavy chain locus (IGH@) at chromosome band 14q32 are frequently observed in mature B-cell neoplasms 1;2 , although a number are now emerging in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) [3] [4] [5] [6] [7] [8] [9] [10] .
The translocation, t(6;14)(p22;q32), has been reported in two independent cases of BCP-ALL 7;8 . It was shown that as a consequence of juxtaposing to the IGH@ enhancer, the partner gene, ID4, was over-expressed 7 . We report here a further 13 cases, indicating the recurrent nature of this translocation in BCP-ALL.
Moreover, we noted an association with other consistent genetic features, including deletions of CDKN2A and PAX5.
Materials and Methods

Patient samples
Samples were received from patients with the translocation, t(6;14)(p22;q32), entered to the UK childhood (UKALLXI, ALL97, or ALL2003) or adult (UKALLXII) ALL treatment trials or the German ALL-BFM 2000 trial (Table 1) , following informed consent in accordance with the Declaration of Helsinki. Institutional Review Board approval was provided by each participating institution.
Cytogenetics and fluorescence in situ hybridisation
Cytogenetics and fluorescence in situ hybridization (FISH) were performed on the same diagnostic samples. The involvement of IGH@ was determined by interphase FISH, using the commercially available IGH@ break-apart probe (Abbott Diagnostics, Illinois, USA). A home-grown dual-color, break-apart probe (consisting of BACs: RP11-377N20 and RP3-498I24) (all clones from Sanger Institute, Hinxton, UK) and a dual-color, dual-fusion probe (IGH@-ID4) ( Figure   1A ) were designed to detect the presence of the translocation in metaphase and interphase, respectively. A commercially available probe to CDKN2A (Abbott Diagnostics, Illinois, USA) and a home-grown probe to PAX5 (BACs: RP11-344B23 and RP11-297B17) were used to evaluate deletions of 9p. FISH mapping was carried out as reported previously 9 .
Long-distance inverse polymerase chain reaction (LDI-PCR)
LDI-PCR from IGHJ was carried out as previously described 9 .
Quantitative real-time PCR
Total cellular RNA, extracted from the same diagnostic samples was available from two patients: 6120 and 16503. Quantitative analysis was performed using Applied Biosytems MGB probes, as previously described 9 .
Results and Discussion
Patient details
Thirteen BCP-ALL patients with t(6;14)(p22;q32) were identified ( Figure 1B /L) and patients were older than expected for BCP-ALL (median 16 years, range 6-48). All patients, for whom outcome data were available (n=10), achieved a complete remission (CR). Two patients died in CR, while 8 remain in CR; 5 for more than 5 years. Although the number of patients is small, their outcome appears to be good, especially among this age group.
Molecular characterisation of 6p22 breakpoints using FISH, LDI-PCR and quantitative real-time PCR
The involvement of IGH@ was confirmed by a positive interphase FISH result in 10 patients with available material (Table 1 ). The 5' IGH@ signal relocated to 6p in metaphases.
As a previous report had indicated involvement of ID4 7 , the dual-color, breakapart FISH probe to ID4 was applied to metaphases ( Figure 1C ). This confirmed that the breakpoint was located close to ID4. The novel dual-color, dual-fusion probe ( Figure 1A Quantitative real-time PCR confirmed over-expression of ID4 (Hs00155465_m1) mRNA in 2 patients with t(6;14)(p22;q32) ( Table 2 ).
Associated cytogenetic changes
An abnormality of the short arm of chromosome 9 (9p) was visible by conventional cytogenetics in 12 patients. Interestingly, this manifested as an isochromosome [i(9)(q10)], a rare mechanism of 9p loss, in 9 patients, also reported in one previously published case 8 . FISH showed either a monoallelic (n=6) or biallelic (n=4) deletion of CDKN2A in all 10 patients tested (Table 1) , including the single case (7294) without a cytogenetically visible deletion of 9p, and an additional submicroscopic 9p deletion in cases 2125 and 12284. A monoallelic deletion of PAX5 was indicated in all cases, either from the presence of an i(9)(q10) (n=9) or by FISH (n=4) ( Table 1) . Two of the 4 patients tested by FISH for PAX5 deletions showed biallelic deletions of CDKN2A.
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ID4 is one of 4 members of the basic helix-loop-helix (bHLH) family of transcription factors, which act as transcription inhibitory proteins 11 . They play a role in regulation of numerous cellular processes, including growth, differentiation, senescence and apoptosis 12 . ID proteins have recently been shown to play a unique role in hematopoeitic cell development 13 .and to induce apoptosis in a variety of cell types 14;15 , including B-lymphocytes 16 . Consistent with a tumor-suppressor role, down-regulation of ID4 has been reported in both mouse and human leukemias at a high frequency, arising from aberrant methylation within the promoter region of the gene 17 . In contrast, ID gene family members have been reported to show over-expression in a range of cancer types [18] [19] [20] [21] [22] , as well as 1 case of BCP-ALL with t(6;14)(p22;q32) .Although CDKN2A and PAX5 deletions have been well documented in all subgroups of ALL [23] [24] [25] , their consistent loss in association with t(6;14)(p22;q32)
indicates an interaction between these pathways and a pivotal role for one or both genes. A recent extensive study showed a decrease in PAX5 mRNA expression in 31.7% of childhood BCP-ALL 25 . They reported diminished PAX5 expression or loss of PAX5 functions occurring via a number of different mechanisms including: deletion (with retention of an apparently normal second allele, suggesting haploinsufficiency); translocation, resulting in PAX5 fusion genes; epigenetic silencing or, more rarely, mutation. The mutation status of the second PAX5 allele could not be determined in this study due to lack of material. This is the first report of a recurrent, novel subgroup of IGH@ positive BCP-ALL with t(6;14)(p22;q32), resulting in deregulated expression of ID4 in cooperation with loss of CDKN2A and PAX5. These findings implicate ID4 as a dominant oncogene in these patients. had an inverted fragment from IGHJ2-3 prior to IGHJ4 segment. (4)t(4;9)(q2?;?),del(5)(q31), der(6)t(6;9)(p2?5;?),t(6;14)(p22;q32),add(9)(p2?), der(9)t(4;9)(q2?;p?)t(5;9)(q31;q22),-17,+22,add (22) 
